Literature DB >> 28126996

Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners.

N Tanna1, C Steel1, S Stagnell2, E Bailey1.   

Abstract

Background Recent evidence suggests that medication-related osteonecrosis of the jaw (MRONJ) can be caused by a number of anti-resorptive and anti-angiongenic agents not limited to bisphosphonates. A working knowledge of these medications is important for dental practitioners.Methods A total of 129 general dental practitioners (GDPs) were surveyed regarding their awareness of MRONJ and its causes.Results More than 90% of the GDPs sampled were unaware of anti-resorptive and anti-angiogenic medications other than bisphosphonates that had the potential to cause MRONJ. Just over 40% of the sampled GDPs were confident to treat patients on oral bisphosphonates in primary care. Much of the reluctance to manage these patients was due to lack of accessible guidelines and unclear protocols.Conclusions The results demonstrate GDP attitudes to patients taking bisphosphonates and highlight how further education is needed to increase confidence to perform simple exodontia amongst this cohort of patients in a primary care setting. As there continues to be a shift to providing dentoalveolar services in primary care, we must ensure that those performing the treatments have a greater understanding of potential MRONJ risks and have guidance as to when to refer.

Entities:  

Mesh:

Year:  2017        PMID: 28126996     DOI: 10.1038/sj.bdj.2017.79

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


  19 in total

Review 1.  Molecular mechanisms of action of bisphosphonates: current status.

Authors:  Anke J Roelofs; Keith Thompson; Sharon Gordon; Michael J Rogers
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 2.  Potential pathophysiological mechanisms in osteonecrosis of the jaw.

Authors:  Regina Landesberg; Victoria Woo; Serge Cremers; Matthew Cozin; Darja Marolt; Gordana Vunjak-Novakovic; Stavroula Kousteni; Srikala Raghavan
Journal:  Ann N Y Acad Sci       Date:  2011-02       Impact factor: 5.691

Review 3.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

Review 4.  Antiresorptives and osteonecrosis of the jaw.

Authors:  Junro Yamashita; Laurie K McCauley
Journal:  J Evid Based Dent Pract       Date:  2012-09       Impact factor: 5.267

5.  Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

Authors:  Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Yang Yao; Zan Shen
Journal:  Int J Clin Oncol       Date:  2013-04-20       Impact factor: 3.402

Review 6.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

Review 7.  Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Authors:  Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

8.  Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.

Authors:  Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacques P Brown; Edward Czerwiński; Marc-Antoine Krieg; Zulema Man; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; José A Román Ivorra; Christian Roux; Eric Vittinghoff; Matthew Austin; Nadia Daizadeh; Michelle N Bradley; Andreas Grauer; Steven R Cummings; Henry G Bone
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

9.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

10.  Chlorhexidine: Hypersensitivity and anaphylactic reactions in the perioperative setting.

Authors:  Eleni Moka; Eriphili Argyra; Ioanna Siafaka; Athina Vadalouca
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Apr-Jun
View more
  8 in total

1.  Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management.

Authors:  Boon Hui Chan; Ruixiang Yee; Rukshini Puvanendran; Seng Bin Ang
Journal:  Singapore Med J       Date:  2018-02       Impact factor: 1.858

2.  A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.

Authors:  Seoyeon Jung; Jaeyeon Kim; Jin Hoo Park; Ki-Yeol Kim; Hyung Jun Kim; Wonse Park
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

3.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

4.  Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals.

Authors:  Wanessa Miranda-Silva; Marco Aurélio Montezuma; Bernar Monteiro Benites; Julia Stephanie Bruno; Felipe Paiva Fonseca; Eduardo Rodrigues Fregnani
Journal:  Support Care Cancer       Date:  2020-03-06       Impact factor: 3.603

5.  General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England.

Authors:  Andrew Sturrock; Philip M Preshaw; Catherine Hayes; Scott Wilkes
Journal:  BMJ Open       Date:  2019-06-17       Impact factor: 2.692

6.  The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey.

Authors:  A Lum Han
Journal:  BMC Oral Health       Date:  2021-03-24       Impact factor: 2.757

7.  Effect of Human Umbilical Cord Matrix-Derived Mesenchymal Stem Cells on Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Gwanghyun Yang; Young-Nam Kim; Hyunjeong Kim; Bu-Kyu Lee
Journal:  Tissue Eng Regen Med       Date:  2021-08-04       Impact factor: 4.451

8.  Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users.

Authors:  Ahmad El-Ma'aita; Noor Da'as; Mais Al-Hattab; Yazan Hassona; Mohammad Al-Rabab'ah; Mohammad-Awni Al-Kayed
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.